New hope for Hard-to-Treat cancers: first human trial of ERAS-0015 begins
NCT ID NCT06983743
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researchers will also look for early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ERAS-0015 (oral drug) alone or combined with pembrolizumab, panitumumab, gemcitabine, or nab-paclitaxel
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have certain RAS mutations and no other good options.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. It is small and may not lead to a proven treatment. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Florida Cancer Specalists
RECRUITINGSarasota, Florida, 34232, United States
-
Massachusetts General Hospital (MG)
RECRUITINGBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Texas at Tyler
RECRUITINGTyler, Texas, 75701, United States